Accumulated evidence has suggested that inactivation or downregulation of FBXW7 may lead to the development of chemoresistance in various cancers, such as breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer (Table 2). This evidence concerns the gene FBXW7 and breast cancer.